Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fibrinolytic function and coronary risk.

I Juhan-Vague1, P Morange, M Christine Alessi

  • 1Laboratoire d'Hématologie, CHU Timone, 13385 Marseille, France.

Current Cardiology Reports
|September 12, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia.

Journal de medecine vasculaire·2021
Same author

Descriptive study of the general practitioners' perception of direct oral anticoagulants and the risk of genital bleeding in women of childbearing age.

Journal de medecine vasculaire·2020
Same author

[Bilateral adrenal hemorrhage under apixaban in primary antiphospholipid syndrome].

La Revue de medecine interne·2019
Same author

[Evaluation of an "Emergency Thrombosis" care system in a university-hospital department of general emergencies].

Journal de medecine vasculaire·2019
Same author

Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: the SAFE-ES study.

Annales de cardiologie et d'angeiologie·2014
Same author

[DVT and combined oral contraceptives: update of the pluridisciplinary CNGOF-FNCGM-GEHT-SFMV group].

Journal de gynecologie, obstetrique et biologie de la reproduction·2013

Imbalances in fibrinolysis, particularly elevated plasminogen activator inhibitor-1 (PAI-1), link insulin resistance, obesity, and cardiovascular disease. Adipose tissue PAI-1 production may drive these increases, impacting heart attack risk.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Molecular Biology

Background:

  • Fibrinolytic potential is regulated by plasminogen activators (e.g., t-PA) and inhibitors (e.g., PAI-1).
  • Insulin resistance syndrome disrupts this balance, increasing PAI-1 and t-PA antigen levels, reducing fibrinolysis, and predicting myocardial infarction.
  • Inflammation may additively contribute to elevated plasma fibrinolytic markers.

Purpose of the Study:

  • To investigate the link between insulin resistance, PAI-1, and cardiovascular disease.
  • To explore the role of adipose tissue in PAI-1 production and its contribution to elevated plasma PAI-1 levels.
  • To examine the genetic influence on PAI-1 expression and its association with myocardial infarction risk.

Main Methods:

  • Analysis of plasma PAI-1 and t-PA antigen levels in the context of insulin resistance and inflammation markers.

Related Experiment Videos

  • Investigation of PAI-1 production by adipose tissue, specifically omental tissue.
  • Examination of the -675 4G/5G PAI-1 gene polymorphism and its association with plasma PAI-1 levels and myocardial infarction.

    • Main Results:

    • Increased plasma PAI-1 and t-PA antigen levels are associated with insulin resistance and myocardial infarction risk.
    • The prognostic value of PAI-1 diminishes with adjustment for insulin resistance, while t-PA's value diminishes with adjustments for insulin resistance and inflammation.
    • Adipose tissue, particularly omental tissue, produces PAI-1, potentially explaining elevated levels in insulin-resistant individuals.
    • The 4G/4G genotype of the PAI-1 -675 4G/5G polymorphism is linked to higher plasma PAI-1 levels.

    Conclusions:

    • PAI-1 may serve as a crucial link between obesity, insulin resistance, and cardiovascular disease.
    • Adipose tissue-derived PAI-1 contributes significantly to hyperinhibition of fibrinolysis in insulin resistance.
    • The genetic predisposition via PAI-1 polymorphism warrants further investigation regarding its impact on myocardial infarction development.